Engene Holdings INC. (ENGNW) — SEC Filings

Overview

Engene Holdings INC. (ENGNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 22, 2025: enGene Holdings Inc. (ENGNW) reported no product revenue for the fiscal year ended October 31, 2025, continuing a history of net losses since inception. The company is heavily dependent on the successful development and commercialization of its lead product candidate, detalimogene voraplasmid (forme

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 3 bearish, 39 neutral. The dominant filing sentiment for Engene Holdings INC. is neutral.

Filing Type Overview

Engene Holdings INC. (ENGNW) has filed 3 10-K, 17 8-K, 1 8-K/A, 5 10-Q, 2 DEF 14A, 1 10-K/A, 4 SC 13G/A, 5 SC 13G, 3 SC 13D/A, 1 S-1/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (42)

• enGene's Future Hinges on Detalimogene as Losses Mount — 10-K · Dec 22, 2025 Risk: high
  enGene Holdings Inc. (ENGNW) reported no product revenue for the fiscal year ended October 31, 2025, continuing a history of net losses since inception. The com
• enGene Holdings Inc. Files 8-K for Material Definitive Agreement — 8-K · Nov 14, 2025 Risk: medium
  On November 12, 2025, enGene Holdings Inc. entered into a material definitive agreement. The company, incorporated in British Columbia, filed a Form 8-K to repo
• 8-K Filing — 8-K · Nov 12, 2025
• enGene Holdings Inc. Amends 8-K Filing — 8-K/A · Oct 2, 2025 Risk: medium
  enGene Holdings Inc. filed an 8-K/A on October 2, 2025, to amend a previous filing regarding events that occurred on July 7, 2025. The amendment pertains to the
• enGene Holdings Inc. Files 8-K Report — 8-K · Sep 30, 2025 Risk: low
  On September 30, 2025, enGene Holdings Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4868 Rue Levy, Su
• enGene's Losses Double Amid R&D Surge, Cash Dwindles — 10-Q · Sep 11, 2025 Risk: high
  enGene Holdings Inc. (ENGNW) reported a significant increase in net loss and operating expenses for the nine months ended July 31, 2025. The net loss surged to
• enGene Holdings Inc. Files 8-K Report — 8-K · Sep 3, 2025 Risk: low
  On September 3, 2025, enGene Holdings Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a R
• enGene Holdings Inc. Files 8-K on Director/Officer Changes — 8-K · Jul 8, 2025 Risk: low
  On July 7, 2025, enGene Holdings Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also i
• enGene's Q2 Loss Widens to $17.3M Amid R&D Ramp-Up — 10-Q · Jun 12, 2025 Risk: high
  enGene Holdings Inc. reported no revenue for the three and six months ended April 30, 2025, consistent with its pre-commercial stage. The company experienced a
• enGene Holdings Inc. Files 8-K on Director/Officer Changes & Shareholder Votes — 8-K · Jun 10, 2025 Risk: medium
  On June 10, 2025, enGene Holdings Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure and election of
• enGene Holdings Inc. Enters Material Definitive Agreement — 8-K · Jun 9, 2025 Risk: medium
  On June 4, 2025, enGene Holdings Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in British
• enGene Holdings Inc. Files 8-K: Board, Officer, and Financial Updates — 8-K · Jun 4, 2025 Risk: low
  On June 3, 2025, enGene Holdings Inc. filed an 8-K report detailing changes in its board of directors and certain officers, along with updates to compensatory a
• enGene Holdings Inc. Files Definitive Proxy Statement — DEF 14A · May 9, 2025 Risk: low
  enGene Holdings Inc. filed its definitive proxy statement on May 9, 2025, for its annual meeting of stockholders. The filing covers the fiscal year ending Octob
• enGene Holdings Inc. Files 8-K on Financials — 8-K · Mar 10, 2025 Risk: low
  On March 10, 2025, enGene Holdings Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4868 Rue Levy, Suite
• enGene Holdings Inc. Files 10-K/A Amendment — 10-K/A · Feb 20, 2025 Risk: low
  enGene Holdings Inc. filed an amendment (10-K/A) on February 20, 2025, for its fiscal year ending October 31, 2024. The company, located at 4868 Rue Levy, Suite
• enGene Holdings Inc. Files Material Definitive Agreement — 8-K · Dec 20, 2024 Risk: medium
  On December 20, 2024, enGene Holdings Inc. filed an 8-K report detailing a material definitive agreement. The filing does not specify the nature of the agreemen
• enGene Holdings Inc. Files 2024 10-K — 10-K · Dec 19, 2024 Risk: medium
  enGene Holdings Inc. filed its 10-K for the fiscal year ending October 31, 2024. The company, located at 4868 Rue Levy, Suite 220, Saint-Laurent, A8, H4R 2P1, r
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 12, 2024
• Forbion Growth Sponsor Files SC 13D/A Amendment for enGene Holdings — SC 13D/A · Nov 1, 2024 Risk: medium
  Forbion Growth Sponsor FEAC I B.V. filed an amendment (No. 2) to its Schedule 13D on October 30, 2024, regarding enGene Holdings Inc. The filing indicates a cha
• enGene Holdings Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 25, 2024 Risk: medium
  On October 24, 2024, enGene Holdings Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• enGene Appoints New CMO, CSO; Director Departs — 8-K · Oct 21, 2024 Risk: medium
  On October 16, 2024, enGene Holdings Inc. announced the appointment of Dr. Robert L. Mass as Chief Medical Officer and Dr. David L. Brown as Chief Scientific Of
• Forbion Growth Sponsor Amends enGene Holdings Stake — SC 13D/A · Oct 18, 2024 Risk: medium
  Forbion Growth Sponsor FEAC I B.V. filed an amendment (No. 1) to its Schedule 13D on October 18, 2024, regarding enGene Holdings Inc. The filing indicates a cha
• enGene Holdings Inc. Files 8-K Report — 8-K · Sep 26, 2024 Risk: low
  On September 26, 2024, enGene Holdings Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• enGene Holdings Inc. 10-Q: Convertible Debentures & Capital Changes — 10-Q · Sep 10, 2024 Risk: medium
  enGene Holdings Inc. filed its 10-Q for the period ending July 31, 2024. The filing details changes in the fair value of convertible debentures embedded derivat
• enGene Holdings Inc. Files 8-K with Office Location — 8-K · Sep 5, 2024 Risk: low
  On September 5, 2024, enGene Holdings Inc. filed an 8-K report. The filing confirms the company's principal executive offices are located at 4868 Rue Levy, Suit
• enGene Appoints Robert Hariri CEO, Mary Ann Gray Departs Board — 8-K · Jul 24, 2024 Risk: medium
  On July 22, 2024, enGene Holdings Inc. announced the appointment of Dr. Robert L. Hariri as Chief Executive Officer and a member of the Board of Directors. Dr.
• enGene Holdings Inc. Files 10-Q for April 30, 2024 — 10-Q · Jun 14, 2024 Risk: medium
  enGene Holdings Inc. filed its 10-Q for the period ending April 30, 2024. The company reported on changes in the fair value of convertible debentures embedded d
• enGene Appoints New CEO, Files 8-K — 8-K · May 15, 2024 Risk: medium
  On May 15, 2024, enGene Holdings Inc. filed an 8-K report detailing several key events. The company announced the appointment of Dr. Robert L. Hariri as Chief E
• enGene Holdings Inc. Announces Annual General Meeting on May 15, 2024 — DEF 14A · Apr 18, 2024 Risk: low
  enGene Holdings Inc. (ENGNW) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. The annual general meeting of enGene Holdings Inc. shareholders w
• enGene Holdings Inc. Files 10-Q for Period Ending January 31, 2024 — 10-Q · Mar 11, 2024 Risk: medium
  enGene Holdings Inc. (ENGNW) filed a Quarterly Report (10-Q) with the SEC on March 11, 2024. enGene Holdings Inc. filed a 10-Q report for the period ending Janu
• enGene Holdings Inc. Files S-1/A Amendment — S-1/A · Feb 27, 2024 Risk: medium
  enGene Holdings Inc. (ENGNW) filed a Amended IPO Registration (S-1/A) with the SEC on February 27, 2024. Filing is an S-1/A amendment for enGene Holdings Inc. C
• SC 13G Filing — SC 13G · Feb 26, 2024
• SC 13G Filing — SC 13G · Feb 23, 2024
• SC 13G Filing — SC 13G · Feb 23, 2024
• SC 13G/A Filing — SC 13G/A · Feb 22, 2024
• Lumira Capital Amends enGene Holdings Ownership Group — SC 13D/A · Feb 21, 2024 Risk: low
  Lumira Capital Investment Management Inc. and its affiliated entities, including Lumira Ventures III and IV, filed an SC 13D/A on February 21, 2024, regarding t
• enGene Reports Material Agreements, Equity Sales, Officer Changes — 8-K · Feb 14, 2024 Risk: medium
  enGene Holdings Inc. filed an 8-K on February 14, 2024, reporting events that occurred on February 13, 2024. The filing details the entry into a material defini
• SC 13G Filing — SC 13G · Feb 14, 2024
• enGene Holdings Inc. Files 2023 Annual Report on Form 10-K — 10-K · Jan 29, 2024 Risk: medium
  enGene Holdings Inc. (ENGNW) filed a Annual Report (10-K) with the SEC on January 29, 2024. enGene Holdings Inc. filed its 10-K report for the fiscal year endin

Risk Profile

Risk Assessment: Of ENGNW's 32 recent filings, 3 were flagged as high-risk, 18 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Engene Holdings INC.'s most recent 10-K filing (Dec 22, 2025):

• Revenue: $0
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Chief Executive Officer
• Dr. Robert L. Mass
• Dr. David L. Brown
• Robert L. Hariri
• Mary Ann Gray
• Anthony Cheung
• Dr. Robert L. Hariri
• Benjamin Rovinski
• Daniel Hetu

Industry Context

The biotechnology sector, particularly in the oncology space, is characterized by rapid innovation and intense competition. Companies like enGene are developing novel genetic medicines, facing challenges in clinical development, regulatory approval, and market access. The landscape includes large pharmaceutical companies with significant R&D budgets and numerous smaller biotech firms vying for funding and market share.

Top Tags

Biotechnology (4) · 8-K (4) · amendment (4) · corporate-governance (3) · filing (3) · material-agreement (3) · financials (3) · sec-filing (3) · 10-Q (3) · enGene Holdings (3)

Key Numbers

• Market Value of Non-Affiliate Common Equity: $154.2M — As of April 30, 2025, indicating current market capitalization for public float.
• Common Shares Outstanding: 66.98M — As of December 17, 2025, representing the total number of shares in circulation.
• Warrant Exercise Price: $11.50 — The price at which warrants can be converted to common shares, impacting potential dilution and future capital.
• Product Revenue: 0 — The company has not generated any product revenue to date, highlighting its pre-commercial stage and reliance on external funding.
• Net loss for nine months ended July 31, 2025: $79.4M — Increased from $39.8M in prior year, indicating doubling of losses.
• Research and development expenses for nine months ended July 31, 2025: $62.8M — Increased from $27.0M, showing significant investment in product development.
• Cash and cash equivalents as of July 31, 2025: $32.6M — Decreased from $173.0M at October 31, 2024, highlighting rapid cash depletion.
• Net cash used in operating activities for nine months ended July 31, 2025: $74.3M — Increased from $28.7M in prior year, reflecting accelerated operational burn.
• Marketable securities - short term as of July 31, 2025: $169.3M — Increased from $65.3M, suggesting a shift in liquidity management.
• Common Shares outstanding as of September 10, 2025: 51,191,771 — Reflects total shares outstanding.
• Net Loss: $17.3M — for the three months ended April 30, 2025, an increase from $12.7M in 2024
• Research and Development Expense: $12.9M — for the three months ended April 30, 2025, up from $9.3M in 2024
• General and Administrative Expense: $4.4M — for the three months ended April 30, 2025, up from $3.4M in 2024
• Cash and Cash Equivalents: $104.9M — as of April 30, 2025, down from $138.5M at October 31, 2024
• Potential Term Loan Advance: $25.0M — available from Hercules Capital upon achieving specified milestones

Related Companies

ENGN

Frequently Asked Questions